CSPC Innovation Pharmaceutical (SHE:300765) unit Jushi Biopharmaceutical obtained China's regulatory approval to conduct clinical trials on antibody-drug conjugate SYS6062.
The antibody-drug conjugate is indicated for the treatment of advanced solid tumors, according to a Shenzhen bourse filing on Friday.
Shares of the pharmaceutical company closed 3% higher Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments